Den Europæiske Union - maltesisk - EMA (European Medicines Agency)

recordati rare diseases - żingu - deġenerazzjoni epatoġenika - oħra tal-passaġġ alimentari u tal-metaboliżmu-prodotti, - trattament tal-marda ta 'wilson.

Den Europæiske Union - maltesisk - EMA (European Medicines Agency)

shionogi b.v. - ospemifene - postmenopause - - ormoni tas-sess u modulaturi ta ' l-ġenitali-sistema, - senshio is indicated for the treatment of moderate to severe symptomatic vulvar and vaginal atrophy (vva) in post-menopausal women.

Den Europæiske Union - maltesisk - EMA (European Medicines Agency)

boehringer ingelheim international gmbh - adalimumab - hidradenitis suppurativa; arthritis, psoriatic; psoriasis; crohn disease; arthritis, juvenile rheumatoid; uveitis; arthritis, rheumatoid; colitis, ulcerative; spondylitis, ankylosing - immunosoppressanti - jekk jogħġbok irreferi għas-sezzjoni 4. 1 tas-sommarju tal-karatteristiċi tal-prodott fid-dokument ta 'informazzjoni tal-prodott.

Den Europæiske Union - maltesisk - EMA (European Medicines Agency)

pierre fabre medicament - binimetinib - melanoma - aġenti antineoplastiċi - binimetinib flimkien ma encorafenib huwa indikat għat-trattament ta ' pazjenti adulti li ma jistgħax jitneħħa kirurġikament, jew li mmetastatizza melanoma bil-braf v600.

Den Europæiske Union - maltesisk - EMA (European Medicines Agency)

fresenius kabi deutschland gmbh - bortezomib - majloma multipla - aġenti antineoplastiċi - bortezomib bħala monoterapija jew flimkien ma 'liposomal doxorubicin jew dexamethasone hu indikat għall-kura ta' pazjenti adulti b'progressiva majeloma multipla li rċevew mill-anqas terapija 1 minn qabel u li diġà għaddew jew li mhumiex tajbin għal trapjant b ' ċelluli staminali ematopojetiċi. bortezomib flimkien ma 'melphalan u prednisone huwa indikat għall-kura ta' pazjenti adulti li ma kienux ikkurati qabel mjeloma multipla li mhumiex eliġibbli għal doża għolja ta 'kimoterapija bi trapjant b' ċelluli staminali ematopojetiċi. bortezomib flimkien ma 'dexamethasone, jew ma' dexamethasone u thalidomide, huwa indikat għall-kura ta 'induzzjoni ta' pazjenti adulti li ma kienux ikkurati qabel mjeloma multipla li huma eliġibbli għal doża għolja ta 'kimoterapija bi trapjant b' ċelluli staminali ematopojetiċi. bortezomib flimkien ma 'rituximab, cyclophosphamide, doxorubicin u prednisone huwa indikat għall-kura ta' pazjenti adulti li ma kienux ikkurati qabel f'forma ta'tubu taċ-ċelluli tal-limfoma li mhumiex tajbin għal trapjant b ' ċelluli staminali ematopojetiċi.

Den Europæiske Union - maltesisk - EMA (European Medicines Agency)

novartis europharm limited  - brolucizumab - deġenerazzjoni makulari mxarrba - oftalmoloġiċi - beovu huwa indikat fl-adulti għall-kura ta neovaskulari (imxarrba) relatata mal-età deġenerazzjoni makulari (amd).

Den Europæiske Union - maltesisk - EMA (European Medicines Agency)

incyte biosciences distribution b.v. - pemigatinib - cholangiocarcinoma - aġenti antineoplastiċi - pemazyre monotherapy is indicated for the treatment of adults with locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (fgfr2) fusion or rearrangement that have progressed  after at least one prior line of systemic therapy.

Den Europæiske Union - maltesisk - EMA (European Medicines Agency)

laboratoire francais du fractionnement et des biotechnologies - eptacog beta (activated) - hemophilia a; hemophilia b - sustanzi kontra l-emorraġija - cevenfacta is indicated in adults and adolescents (12 years of age and older) for the treatment of bleeding episodes and for the prevention of bleeding in those undergoing surgery or invasive procedures in the following patient groups:in patients with congenital haemophilia with high-responding inhibitors to coagulation factors viii or ix (i. ≥5 bethesda units (bu)); in patients with congenital haemophilia with low titre inhibitors (bu.

Den Europæiske Union - maltesisk - EMA (European Medicines Agency)

roche registration gmbh - faricimab - wet macular degeneration; macular edema; diabetes complications - oftalmoloġiċi - vabysmo is indicated for the treatment of adult patients with:neovascular (wet) age-related macular degeneration (namd),visual impairment due to diabetic macular oedema (dme).

Den Europæiske Union - maltesisk - EMA (European Medicines Agency)

taiho pharma netherlands b.v. - futibatinib - cholangiocarcinoma - aġenti antineoplastiċi - lytgobi monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (fgfr2) fusion or rearrangement that have progressed after at least one prior line of systemic therapy.